Abstract
Purpose
To investigate the aerosolization and behaviour of microparticles of salmeterol xinafoate (SX) and fluticasone propionate (FP) suspended in hydrofluoroalkane (HFA) propellant.
Methods
Microcrystals of SX and FP were produced from poly(ethylene glycol) by antisolvent crystallization. The suspension behaviour and aerosolization of the microcrystals when formulated as metered dose inhalers (MDIs) in HFA 134a propellant was compared with that of microparticles produced by micronization (mSX and mFP) using a glass twin stage impinger and by laser light diffraction using a pressurized cell.
Results
FP microparticles underwent non-reversible aggregation in suspension as seen by a doubling in the volume median diameter compared to the raw material. The degree of aggregation of SX particles in suspension was found to decrease as the particle size of the original particles increased. However, because the SX aggregate size was lowest for the particles with the smallest initial size (mSX), the highest fine particle fraction (FPF) of SX was obtained from a suspension of mSX. The FPFs following aerosolization of FP suspensions were similar although the FPF was lowest for particles with the largest original size.
Conclusions
The size of the aggregates in the HFA suspensions was found to correlate directly with the FPFs determined by impaction.
Similar content being viewed by others
References
R. Dalby, and J. Suman. Inhalation therapy: technological milestones in asthma treatment. Adv. Drug Del. Rev. 55:779–791 (2003).
J. N. Pritchard. The influence of lung deposition on clinical response. J. Aerosol Med. 14:S19–S26 (2001).
J. Berry, S. Heimbecher, J. L. Hart, and J. Sequeira. Influence of the metering chamber volume and actuator design on the aerodynamic particle size of a metered dose inhaler. Drug Dev. Ind. Pharm. 29:865–876 (2003).
G. Brambilla, D. Ganderton, R. Garzia, D. Lewis, B. Meakin, and P. Ventura. Modulation of aerosol clouds produced by pressurised inhalation aerosols. Int. J. Pharm. 186:53–61 (1999).
C. Vervaet, and P. R. Byron. Drug–surfactant–propellant interactions in HFA-formulations. Int. J. Pharm. 186:13–30 (1999).
H. D. C. Smyth. The influence of formulation variables on the performance of alternative propellant-driven metered dose inhalers. Adv. Drug Del. Rev. 55:807–828 (2003).
I. Gonda. Development of a systematic theory of suspension inhalation aerosols. I. A framework to study the effects of aggregation on the aerodynamic behaviour of drug particles. Int. J. Pharm. 27:99–116 (1985).
C. Hak-Kim, and I. Gonda. Development of a systematic theory of suspension inhalation aerosols. II. Aggregates of monodisperse particles nebulized in polydisperse droplets. Int. J. Pharm. 41:147–157 (1988).
T. E. Tarara, M. S. Hartman, H. Gill, A. A. Kennedy, and J. G. Weers. Characterization of suspension-based metered dose inhaler formulations composed of spray-dried budesonide microcrystals dispersed in HFA-134a. Pharm. Res. 21:1607–1614 (2004).
Y. Michael, B.Z. Chowdhry, I.C. Ashurst, M.J. Snowden, C. Davies-Cutting, and S. Gray. The physico-chemical properties of salmeterol and fluticasone propionate in different solvent environments. Int. J. Pharm. 200:279–288 (2000).
J. Berry, L. Kline, V. Naini, S. Chaudhry, J. Hart, and J. Sequeira. Influence of the valve lubricant on the aerodynamic particle size of a metered dose inhaler. Drug Dev. Ind. Pharm. 30:267–275 (2004).
I. D. Peyron, I. L. Britto, L. B. Benissan, and B. Z. Tardieu. Development and performance of a new hydrofluoroalkane (HFA 134a)-based metered dose inhaler (MDI) of salmeterol. Respir. Med. 99:S20–S30 (2005).
R. Ashayer, P. F. Luckham, S. Manimaaran, and P. Rogueda. Investigation of the molecular interactions in a pMDI formulation by atomic force microscopy. Eur. J. Pharm. Sci. 21:533–543 (2004).
A. Cripps, M. Riebe, M. Schulze, and R. Woodhouse. Pharmaceutical transition to non-CFC pressurized metered dose inhalers. Respir. Med. 94:S3–S9 (2000).
Y. Michael, M. J. Snowden, B. Z. Chowdhry, I. C. Ashurst, C. J. Davies-Cutting, and T. Riley. Characterisation of the aggregation behaviour in a salmeterol and fluticasone propionate inhalation aerosol system. Int. J. Pharm. 221:165–174 (2001).
G. Buckton. Characterisation of small changes in the physical properties of powders of significance for dry powder inhaler formulations. Adv. Drug Del. Rev. 26:17–27 (1997).
M. Davies, A. Brindley, X. Y. Chen, M. Marlow, S. W. Doughty, I. Shrubb, and C. J. Roberts. Characterization of drug particle surface energetics and Young’s modulus by atomic force microscopy and inverse gas chromatography. Pharm. Res. 22:1158–1166 (2005).
E. M. Phillips, and P. R. Byron. Surfactant promoted crystal growth of micronized methylprednisolone in trichloromonofluoromethane. Int. J. Pharm. 110:9–19 (1994).
D. Murnane, C. Marriott, and G. P. Martin. Comparison of salmeterol xinafoate microparticle production by conventional and novel antisolvent crystallization. Eur. J. Pharm. Biopharm. 69:94–105 (2008).
D. Murnane, G. P. Martin, and C. Marriott. Validation of a reverse-phase high performance liquid chromatographic method for concurrent assay of a weak base (salmeterol xinafoate) and a pharmacologically active steroid (fluticasone propionate). J. Pharm. Biomed. Anal. 40:1149–1154 (2006).
S. A. Jones, G. P. Martin, and M. B. Brown. High-pressure aerosol suspensions—a novel laser diffraction particle sizing system for hydrofluoroalkane pressurised metered dose inhalers. Int. J. Pharm. 302:154–165 (2005).
British Pharmacopoeia, The Stationary Office, London, 2007.
B. Y. Shekunov, J. C. Feeley, A. H. L. Chow, H. H. Y. Tong, and P. York. Physical properties of supercritically-processed and micronised powders for respiratory drug delivery. KONA. 20:178–187 (2002).
M. D. Louey, M. Van Oort, and A. J. Hickey. Aerosol dispersion of respirable particles in narrow size distributions using drug-alone and lactose-blend formulations. Pharm. Res. 21:1207–1213 (2004).
D. Murnane, C. Marriott and G. P. Martin. Crystallization and crystallinity of fluticasone propionate. Crys. Growth Des. (2008), (in press).
P. M. Young, R. Price, D. Lewis, S. Edge, and D. Traini. Under pressure: predicting pressurized metered dose inhaler interactions using the atomic force microscope. J. Colloid Interface Sci. 262:298–302 (2003).
S. A. Jones, G. P. Martin, and M. B. Brown. Manipulation of beclomethasone–hydrofluoroalkane interactions using biocompatible macromolecules. J. Pharm. Sci. 95:1060–1074 (2006).
H. H. Y. Tong, B. Y. Shekunov, P. York, and A. H. L. Chow. Influence of polymorphism on the surface energetics of salmeterol xinafoate crystallized from supercritical fluids. Pharm. Res. 19:640–648 (2002).
H. Steckel, and B. W. Muller. Metered-dose inhaler formulation of fluticasone-17-propionate micronized with supercritical carbon dioxide using the alternative propellant HFA-227. Int. J. Pharm. 173:25–33 (1998).
Acknowledgements
The authors are grateful to MedPharm Ltd. and King’s College London for financial support of this study. We also thank Dr. SA Jones for use of the high pressure circulatory laser diffraction system.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Murnane, D., Martin, G.P. & Marriott, C. Investigations into the Formulation of Metered Dose Inhalers of Salmeterol Xinafoate and Fluticasone Propionate Microcrystals. Pharm Res 25, 2283–2291 (2008). https://doi.org/10.1007/s11095-008-9622-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11095-008-9622-3